Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
GTHX Price Action
GTHX RSI Chart
GTHX Valuation
GTHX Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
GTHX Fundamentals
GTHX Revenue
GTHX Earnings
GTHX Profitability
GTHX Investor Care
Revenue & Growth
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2024 | 84.0M | 58.2M | 0 | 0 |
| 2023 | 57.3M | 89.2M | 77.9M | 82.5M |
| 2022 | 24.2M | 28.1M | 46.8M | 51.3M |
| 2021 | 59.5M | 64.0M | 42.2M | 31.5M |
| 2020 | 0 | 15.4M | 30.4M | 45.3M |
| 2015 | 0 | 0 | 0 | 522.0K |
Get all data in R, Python etc through our Historical Stock Data APIs
G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor can protect bone marrow and reduce hematologic adverse events (AEs), as well as improve emerging treatments through myeloprotection which improve patients' overall anti-tumor immune responses combination with the antibody-drug conjugate; and treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
| CEO | Mr. John E. Bailey Jr. |
|---|---|
| WEBSITE | g1therapeutics.com |
| SECTOR | Healthcare |
| INDUSTRY | Biotechnology |
| EMPLOYEES | 170 |
